Kodiak Sciences Inc. Unveils Dual-Mechanism Glaucoma Therapy at ACS Fall 2025, Introducing AI-Enabled VETi™ Headset for Clinical Trials
Reuters
Aug 20
<a href="https://laohu8.com/S/KOD">Kodiak Sciences Inc.</a> Unveils Dual-Mechanism Glaucoma Therapy at ACS Fall 2025, Introducing AI-Enabled VETi™ Headset for Clinical Trials
Kodiak Sciences Inc., a biotechnology company focused on retinal therapeutics, has announced that it will present its pipeline programs targeting glaucoma at the American Chemical Society $(ACS.AU)$ Fall 2025 Meeting. The presentation, scheduled for August 19, 2025, will be delivered by Dr. Dolly S. Chang, the Chief Scientific Officer of Kodiak Sciences. The presentation, titled "Unmet clinical endpoints and therapeutics for retinal diseases: Challenges and innovations," will explore the company's advancements, particularly in dual-mechanism therapies aimed at glaucoma optic neuropathy. Kodiak Sciences is employing its Antibody Biopolymer Conjugate Drug (ABCD) platform to develop a treatment combining a novel small-molecule NLRP3 inhibitor with an intraocular pressure-lowering agent. The treatment is designed for quarterly intravitreal injections. The results of these advancements will be shared during the symposium "EyeNovation: Small Molecule Drug Discovery for Common Ocular Diseases." Slides of the presentation will be available on Kodiak's website following the event.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kodiak Sciences Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: SF54848) on August 19, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.